Literature DB >> 24812268

Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes.

Matthew D Hall1, Katherine A Telma1, Ki-Eun Chang1, Tobie D Lee1, James P Madigan1, John R Lloyd2, Ian S Goldlust3, James D Hoeschele4, Michael M Gottesman5.   

Abstract

The platinum drugs cisplatin, carboplatin, and oxaliplatin are highly utilized in the clinic and as a consequence are extensively studied in the laboratory setting. In this study, we examined the literature and found a significant number of studies (11%-34%) in prominent cancer journals utilizing cisplatin dissolved in DMSO. However, dissolving cisplatin in DMSO for laboratory-based studies results in ligand displacement and changes to the structure of the complex. We examined the effect of DMSO on platinum complexes, including cisplatin, carboplatin, and oxaliplatin, finding that DMSO reacted with the complexes, inhibited their cytotoxicity and their ability to initiate cell death. These results render a substantial portion of the literature on cisplatin uninterpretable. Raising awareness of this significant issue in the cancer biology community is critical, and we make recommendations on appropriate solvation of platinum drugs for research. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24812268      PMCID: PMC4153432          DOI: 10.1158/0008-5472.CAN-14-0247

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

Review 1.  The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.

Authors:  Matthew D Hall; Mitsunori Okabe; Ding-Wu Shen; Xing-Jie Liang; Michael M Gottesman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

Review 2.  Origin and evolution of high throughput screening.

Authors:  D A Pereira; J A Williams
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

3.  Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents.

Authors:  C M Giandomenico; M J Abrams; B A Murrer; J F Vollano; M I Rheinheimer; S B Wyer; G E Bossard; J D Higgins
Journal:  Inorg Chem       Date:  1995-03       Impact factor: 5.165

4.  Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA.

Authors:  M S Davies; S J Berners-Price; T W Hambley
Journal:  Inorg Chem       Date:  2000-12-11       Impact factor: 5.165

Review 5.  Fundamental studies with cisplatin.

Authors:  B Rosenberg
Journal:  Cancer       Date:  1985-05-15       Impact factor: 6.860

Review 6.  Cellular processing of platinum anticancer drugs.

Authors:  Dong Wang; Stephen J Lippard
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

7.  Stability of carboplatin and oxaliplatin in their infusion solutions is due to self-association.

Authors:  Anthony J Di Pasqua; Deborah J Kerwood; Yi Shi; Jerry Goodisman; James C Dabrowiak
Journal:  Dalton Trans       Date:  2011-04-04       Impact factor: 4.390

8.  Towards Antitumor Active trans-Platinum Compounds.

Authors:  Sheena M Aris; Nicholas P Farrell
Journal:  Eur J Inorg Chem       Date:  2009-04-01       Impact factor: 2.524

9.  Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells.

Authors:  Shu-Jun Chiu; Yi-Jang Lee; Tzu-Sheng Hsu; Wen-Shu Chen
Journal:  Chem Biol Interact       Date:  2009-09-06       Impact factor: 5.192

Review 10.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

View more
  61 in total

1.  Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.

Authors:  Wilma Neumann; Brenda C Crews; Menyhárt B Sárosi; Cristina M Daniel; Kebreab Ghebreselasie; Matthias S Scholz; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2014-10-15       Impact factor: 3.466

2.  Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells.

Authors:  Mario Niepel; Marc Hafner; Mirra Chung; Peter K Sorger
Journal:  Curr Protoc Chem Biol       Date:  2017-06-19

3.  In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes.

Authors:  Kevin M Knopf; Brendan L Murphy; Samantha N MacMillan; Jeremy M Baskin; Martin P Barr; Eszter Boros; Justin J Wilson
Journal:  J Am Chem Soc       Date:  2017-09-26       Impact factor: 15.419

4.  STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells.

Authors:  Nicole C Schmitt; Sumita Trivedi; Robert L Ferris
Journal:  Mol Cancer Ther       Date:  2015-07-03       Impact factor: 6.261

5.  Allantoin reduces cell death induced by cisplatin: possible implications for tumor lysis syndrome management.

Authors:  Janaina Fernandes; Gisele Cardoso de Amorim; Tallita Eduarda da Veiga; Jesiel Cardoso; Alberto Cardoso Arruda; Mara Silvia Pinheiro Arruda; Morgana T L Castelo-Branco
Journal:  J Biol Inorg Chem       Date:  2019-04-27       Impact factor: 3.358

6.  Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.

Authors:  Marina Stukova; Matthew D Hall; Samantha D Tsotsoros; James P Madigan; Nicholas P Farrell; Michael M Gottesman
Journal:  J Inorg Biochem       Date:  2015-05-14       Impact factor: 4.155

7.  The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.

Authors:  Ki-Eun Chang; Bih-Rong Wei; James P Madigan; Matthew D Hall; R Mark Simpson; Zhengping Zhuang; Michael M Gottesman
Journal:  Mol Cancer Ther       Date:  2014-11-05       Impact factor: 6.261

8.  Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division.

Authors:  John Michael Replogle; Wen Zhou; Adrianna E Amaro; James M McFarland; Mariana Villalobos-Ortiz; Jeremy Ryan; Anthony Letai; Omer Yilmaz; Jason Sheltzer; Stephen J Lippard; Uri Ben-David; Angelika Amon
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-17       Impact factor: 11.205

9.  Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs.

Authors:  Justin C Jagodinsky; Agnieszka Sulima; Yiqi Cao; Joanna E Poprawski; Burchelle N Blackman; John R Lloyd; Rolf E Swenson; Michael M Gottesman; Matthew D Hall
Journal:  J Biol Inorg Chem       Date:  2015-09-01       Impact factor: 3.358

10.  The curcuminoid, EF-24, reduces cisplatin-mediated reactive oxygen species in zebrafish inner ear auditory and vestibular tissues.

Authors:  Jerry D Monroe; Matthew H Millay; Blaine G Patty; Michael E Smith
Journal:  J Clin Neurosci       Date:  2018-09-20       Impact factor: 1.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.